Rizatriptan Benzoate
NDC Package 76282-463-06
Package Information
Rizatriptan Benzoate is tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. Marketed by Exelan Pharmaceuticals Inc., this product is identified by NDC 76282-463 and is authorized under FDA application ANDA204339.
Identification & Billing
- RxCUI: 312840 - rizatriptan benzoate 5 MG Oral Tablet
- RxCUI: 312840 - rizatriptan 5 MG Oral Tablet
- RxCUI: 312840 - rizatriptan 5 MG (as rizatriptan benzoate 7.265 MG) Oral Tablet
- RxCUI: 314209 - rizatriptan benzoate 10 MG Oral Tablet
- RxCUI: 314209 - rizatriptan 10 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 76282 - Exelan Pharmaceuticals Inc.
- 76282-463 - Rizatriptan Benzoate
- 76282-463-06 - 6 TABLET in 1 BLISTER PACK
- 76282-463 - Rizatriptan Benzoate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (76282-463). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 76282-463-06 identifies a specific commercial package of 6 tablet in 1 blister pack of Rizatriptan Benzoate, labeled by Exelan Pharmaceuticals Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Exelan Pharmaceuticals Inc. on June 06, 2017. The current certification is valid through December 31, 2021.
How is this Exelan Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 76282046306. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 6 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.